Neuropilin 1

Neuropilin-1 is a is_associated_with::protein that in humans is encoded by the NRP1 is_associated_with::gene. In humans, the neuropilin 11 gene is located at 10p11.22. This is one of two human is_associated_with::neuropilins.

Interactions
Neuropilin 1 has been shown to interact with is_associated_with::Vascular endothelial growth factor A.

Implication in cancer
Neuropilin 1 has been implicated in the vascularization and progression of cancers. In vitro and in vivo mouse studies have shown membrane bound NRP1 to be proangiogenic and promotes the vascularization of prostate tumors. NRP1 expression levels have been shown to be elevated in a number of human patient tumor samples, including brain, prostate, breast, colon, and lung cancers and is associated with is_associated_with::metastasis. Elevated NRP1 expression is also correlated with the invasiveness of non-small cell lung cancer both in vitro and in vivo.

Target for cancer therapies
As a is_associated_with::co-receptor for VEGF, NRP1 is a potential target for cancer therapies. A synthetic peptide, EG3287, was generated in 2005 and has been shown to block NRP1 activity. EG3287 has been shown to induce is_associated_with::apoptosis in tumor cells with elevated NRP1 expression. A patent for EG3287 was filed in 2002 and approved in 2003. As of 2015 there were no clinical trials ongoing or completed for EG3287 as a human cancer therapy.

Interestingly, soluble NRP1 has the opposite effect of membrane bound NRP1 and has anti-VEGF activity. In vivo mouse studies have shown that injections of sNRP-1 inhibits progression of is_associated_with::acute myeloid leukemia in mice.